Solutions

Online Inquiry

CAR-T In Vitro Efficacy Services with OncoSolid™ Peritoneal Metastatic Colorectal Cancer Organoid Models

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Peritoneal Metastatic Colorectal Cancer Organoid Models

Peritoneal metastatic (PM) colorectal cancer is an advanced malignant that makes up 10% of colorectal cancer. Though surgery resection and chemotherapies are functional clinical options, the poor survival and high recurrence rate of cancer demonstrate the strong demand for developing more effective clinical approaches. Organoid is a valuable in vitro tumor culture that recapitulates the molecular and phenotypic features of individual-patient tumor tissue and plays a key role in tumor profiling and promising therapy development.

Peritoneal Metastatic Colorectal Cancer Organoid Models at Creative Biolabs

Creative Biolabs is a lead service provider in immunotherapy, and now we present preclinical cancer organoid models and their use for efficacy tests of the modified immune cell products.

Workflow

Peritoneal Metastatic Colorectal Cancer Organoid Models

Fig.1 Working step of Peritoneal metastatic colorectal cancer organoid generation and use for evaluation. (Ubink, et al., 2019)

Various Sources of Tumor Tissue

Peritoneal Metastatic Colorectal Cancer Organoid Models Fig.2 Formation of Peritoneal Metastatic
Colorectal Cancer. (Baaten, et al., 2020)

Source of Tumor Tissue

Malignant ascites
Biopsies of peritoneal metastasis
Surgically resect tumor tissue

Complete Cancer Organoid Characterization System

Using cut-in-edge biological techniques and methods, we perform a thorough characterization of organoids and initial tumor tissue to profile the features of the organoid model for the following application.

Subtypes of tumor tissue

Application of Peritoneal Metastatic Colorectal Cancer Organoids Original tumor tissue

Application of Peritoneal Metastatic Colorectal Cancer Organoids Cancer organoids

Application of Peritoneal Metastatic Colorectal Cancer Organoids Organoids xenograft

Histopathological Features

Techniques

Acid Schiff staining
H&E staining
Immunohistochemical staining (IHC)
Western bolt analysis

Functions

Tumor-associated protein
Mucus
Histological pattern
Diverse morphologies in vitro
Proteomic Analysis

Genomic Features

Whole genome sequencing
Whole exome sequencing
RNA sequencing
Epigenomics
Proteomic Analysis

Copy-number aberrations (CNA)
Pathogenic single-nucleotide variants (SNV)
Gene mutations
Molecular subtypes
Genetic heterogeneity
Complex chromosomal rearrangements

CAR-T Efficacy Test Using Cancer Organoids

The organoid model is of clinical relevance since the organoid response is correlated to cancer patients and hence can be used to predict patients' responses.

Incubation system

The collected organoid cultures are co-culture in a modified medium that can support both cell growth.

Data analysis

Live‐cell imaging and flow cytometric analysis.
Organoid engineered to express fluorescent protein for tagging and tracking.

Report

Cell identity
Cell replication
Cell viability
ATP levels
Cell migration

Application of Peritoneal Metastatic Colorectal Cancer Organoids

Application of Peritoneal Metastatic Colorectal Cancer Organoids (Giuliano & Pagès, 2013)

Tumor Biology

Understand the mechanism of tumor formation, metastasis, and resistance action.

Application of Peritoneal Metastatic Colorectal Cancer Organoids (Creative Biolabs)

Novel Therapy Discovery

Help development new treatment strategies.

Application of Peritoneal Metastatic Colorectal Cancer Organoids (Ubink, et al., 2019)

Drug Sensitivity Test

Immunotherapy, chemotherapy, and the combined treatment regime.

Key Features

Cancer organoid models recapitulate the heterogenous of patients and tumor tissues
Establish an organoid platform for cancer study and treatment development
Highly relevant pre-clinical PM models
Enough organoid cultures allow various characterizations

Related CAR-T Products at Creative Biolabs

As the leading biotech in the immunotherapy field, we provide multiple products for chimeric antigen receptor (CAR) T cell construction and lateral in vitro cytotoxicity tests. Our products include CAR vectors, viral particles, immune cell products, and so on. Moreover, we offer customized CAR-T, CAR-MA, CAR-NK, and TCR-T therapy development services.

Target Antigen	Target Description	CAR-T Product
CEA	Increased CEA in serum is an indicator of advanced or peritoneal metastases of colorectal cancer. CEA has become a potential target for CAR-T therapy and is used for cancer treatment.	Anti-CEA CAR-T

Organoid is the most clinically relevant in vitro model for many healthy tissues and cancer with the advantage of easy manipulation. We offer a living biobank of cancer organoid models for CAR-T therapy development for complicated solid tumors. Please contact us and learn more about the services.

References

Ubink, I.; et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy. The British journal of surgery. 2019, 106 (10): 1404-1414.
Giuliano, S.; Pagès, G. Mechanisms of resistance to anti-angiogenesis therapies. Biochimie. 2019, 95 6: 1110-9.
Kranenburg, O.; et al. Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges. Frontiers in oncology. 2021, 11: 650098.
Baaten, I. C. P. A.; et al. Colorectal cancer peritoneal metastases: Biology, treatment and next steps. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2020, 46(4 Pt A): 675-683.